Actionable news
All posts from Actionable news
Actionable news in SRPT: Sarepta Therapeutics, Inc.,

Sarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines'

NEW YORK (TheStreet) -- Shares of Sarepta Therapeutics (SRPT) were retreating mid-Wednesday morning as speculation mounts that the company's Duchenne muscular dystrophy therapy eteplirsen could get a "differing-professional-opinions" proceeding by the FDA.

Analysts at Janney said in a note cited by Barron's that "if the DPO clause has been invoked, the final decision on eteplirsen may now rest with the agency commissioner, which suggests the large N, randomized-study faction within the agency has the upper...